Clinical Trial Update: Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation [Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 2 trial evaluating adjuvant docetaxel (Taxotere) after prostatectomy and radiation in high-risk prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Sponsor: Stanford University | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED